Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s

Authors :: Robin Katie Kelley
Helen He
Jian Huang
Ratislav Bahleda
Andrew X. Zhu
Lipika Goyal
Cinta Hierro
H.-T. Arkenau
Milind Javle
Robert Winkler
Daniel H. Ahn
Ben Tran
Funda Meric-Bernstam
Source :: Annals of Oncology. 29:ix49-ix50
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Chemotherapy
business.industry
medicine.medical_treatment
05 social sciences
Hematology
Chemotherapy regimen
03 medical and health sciences
0302 clinical medicine
Oncology
Fibroblast growth factor receptor
030220 oncology & carcinogenesis
0502 economics and business
Cancer research
Medicine
050211 marketing
In patient
business
Previously treated

Full Text Access

Tools